Latest news with #AgilentTechnologies
Time of India
3 days ago
- Business
- Time of India
Agilent opens new biopharma centre in Hyd
Hyderabad: US-based analytical and clinical laboratory technologies player Agilent Technologies Inc has opened its new biopharma experience centre in Hyderabad. The facility will offer advanced laboratory technologies, expert training, and regulatory-ready workflows to expedite the development of high-quality, life-saving medicines. It will provide comprehensive solutions in chromatography, mass spectrometry, cell analysis, and lab informatics, enabling companies to simulate real lab environments and develop market-ready solutions, Agilent said. The new centre will also drive collaboration between industry and academia, support faster R&D, and align with international regulatory standards. Inaugurating the new facility on Tuesday, Telangana IT and industries minister Duddila Sridhar Babu said the centre will bolster Hyderabad's position as a leader in life sciences and healthcare innovation. He said Hyderabad's robust life sciences ecosystem contributes to nearly one-third of India's pharmaceutical production and 40% of bulk drug exports. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad Agilent Technologies CEO Padraig McDonnell said: "India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation. This new centre reflects our commitment to delivering integrated solutions that help bring life-changing therapies to market faster and more efficiently. It also reinforces our support for the 'Make-in-India' initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions. " He said the investment is part of the company's broader strategy to expand its footprint in India and position it as a strategic hub in its global innovation roadmap.
Hans India
31-07-2025
- Business
- Hans India
Agilent Supports India's Global Biopharma Ambitions with State-of-the-Art Experience Center in Hyderabad
Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, today announced the inauguration of its new Biopharma Experience Center in Hyderabad, Telangana. The facility marks a significant investment in India's rapidly growing life sciences ecosystem and reflects Agilent's long-term commitment to advancing biopharmaceutical innovation both locally and globally. The center was inaugurated by Shri Duddila Sridhar Babu, Hon'ble Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana, in the presence of Agilent President and CEO Padraig McDonnell, along with senior leaders from India's pharmaceutical and biopharma sectors. The new Agilent Biopharma Experience Center in Hyderabad presents a major opportunity to accelerate the city's leadership in life sciences and healthcare innovation. Designed to support the full drug development journey, the center brings together advanced lab technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines faster and more efficiently. It offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics, allowing companies to simulate real lab environments, test for quality and compliance, and co-create market-ready solutions tailored to both Indian and global needs. For Hyderabad's vibrant ecosystem of startups, academic institutions, and skilled professionals, the center unlocks direct access to global expertise, cutting-edge instrumentation, and real-world application environments. It supports faster R&D, hands-on training aligned with international regulatory standards, and stronger collaboration between industry and academia. By addressing critical challenges in biosimilars, biologics, and precision medicine, the facility strengthens Hyderabad's position as a trusted global hub for next-generation drug development, and a key contributor to India's biopharma growth story. 'India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,' said Padraig McDonnell, CEO, Agilent Technologies. 'Our future will be defined by continued innovation and a relentless focus on our customers. This new center reflects our commitment to delivering integrated solutions that help bring life-changing therapies to market faster and more efficiently. It also reinforces our support for the 'Make-in-India' initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions.' Located in the heart of India's life sciences capital, the center is designed to address critical gaps in analytical capabilities and regulatory readiness for biopharma companies. It will serve as a hub for innovation and collaboration, supporting the development of biologics, biosimilars, and precision medicine. Shri Duddila Sridhar Babu, Hon'ble Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana said, 'Hyderabad has emerged as a complete healthcare and life sciences ecosystem—from drug discovery and clinical trials to world-class hospitals and affordable, high-quality patient care. We are proud to host eight of the top ten global pharma companies, five of India's leading healthcare chains, and over 230 USFDA-approved manufacturing facilities. Contributing nearly one-third of India's pharmaceutical production and 40% of bulk drug exports, Telangana is making a strong impact both nationally and globally. With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The launch of the Agilent Biopharma Experience Center is a significant milestone in strengthening Telangana's position as a global leader in life sciences, and a valuable addition to our expanding innovation-driven ecosystem.' Hyderabad offers one of the most mature and future-focused life sciences ecosystems in India, combining deep industry expertise, strong R&D capabilities, and a supportive policy environment. With its legacy in generics and a growing focus on advanced therapies, the city is well-positioned for the next phase of healthcare innovation. The launch of the Agilent Biopharma Experience Center builds on this foundation, introducing advanced analytical and regulatory capabilities that support both local innovation and global delivery. This capital investment is part of Agilent's broader three-to-five-year India growth strategy, which includes expanding its footprint, deepening customer partnerships, and positioning India as a strategic hub in Agilent's global innovation and profitability roadmap. The India Solution Center in Manesar, launched earlier this year, further reflects this ongoing commitment—contributing to Agilent's efforts to enhance its presence and capabilities in one of its fastest-growing, high-priority markets globally. 'Agilent is already working closely with many of India's leading biopharma companies,' added McDonnell. 'With this center, we aim to strengthen those relationships and co-create solutions that meet the evolving needs of the Indian and global markets.' This milestone marks a new chapter in Agilent's journey with India—deepening collaboration, accelerating innovation, and contributing to a healthier, more sustainable future.
New Indian Express
30-07-2025
- Business
- New Indian Express
Agilent opens its Indian biopharma capability center in Hyderabad
CHENNAI: Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, has inaugurated its new Biopharma Capability Center in Hyderabad. The facility represents a significant investment in India's expanding life sciences ecosystem and aligns with the U.S.-based company's broader three-to-five-year growth strategy for the country. The center was inaugurated by Telangana's Minister for Information Technology, Electronics, Communications, and Industries, Duddila Sridhar Babu, in the presence of Agilent's global CEO Padraig McDonnell. Designed to support the entire drug development process, the center features advanced laboratory technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines. It will serve as a hub for innovation and collaboration, focusing on the development of biologics, biosimilars, and precision medicine. The facility offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics. These capabilities allow companies to simulate real laboratory environments, test for quality and compliance, and co-create solutions tailored to both Indian and global markets. For Hyderabad's biopharma startups, academic institutions, and skilled professionals, the center provides access to global expertise, cutting-edge instrumentation, and real-world application environments. It supports accelerated R&D, hands-on training aligned with international regulatory standards, and fosters stronger industry-academia collaboration. 'India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,' said Padraig McDonnell, CEO of Agilent Technologies. 'Our future will be shaped by continued innovation and a relentless focus on our customers.' 'This new experience center reinforces our support for the 'Make-in-India' initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions,' McDonnell added. Commenting on the launch, Minister Sridhar Babu said, 'With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The Agilent Biopharma Experience Center is a significant milestone that strengthens Telangana's position as a global life sciences leader and adds value to our growing innovation-driven ecosystem.' Telangana currently accounts for nearly one-third of India's pharmaceutical production and 40% of bulk drug exports. Hyderabad boasts one of the most mature and future-focused life sciences ecosystems in India, with deep industry expertise, strong R&D capabilities, and a conducive policy environment. Building on the city's legacy in generics and increasing emphasis on advanced therapies, the new center adds cutting-edge analytical and regulatory capabilities that support local innovation and global delivery. Earlier this year, Agilent also launched its India Solution Center in Manesar. With this expansion, the company is deepening customer partnerships and positioning India as a strategic hub in its global innovation and growth roadmap. 'Agilent is already working closely with many of India's leading biopharma companies,' McDonnell said. 'With this center, we aim to strengthen those relationships and co-create solutions that address the evolving needs of both Indian and global markets.'
The Hindu
29-07-2025
- Business
- The Hindu
Agilent Tech opens Biopharma Experience Centre in Hyderabad
NYSE-listed global leader in Life Sciences, diagnostics and applied chemical markets Agilent Technologies has established a Biopharma Experience Centre in Hyderabad to support the drug development journey of its customers. End-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis and lab informatics that will allow its customers to simulate real lab environments are available. The companies can test for quality and compliance and co-create market-ready solutions, Industries and IT Minister Babu's office said after he inaugurated the facility on Tuesday. Launch of the facility is a significant milestone in strengthening Telangana's position as a global leader in Life Sciences and a valuable addition to expanding innovation-driven ecosystem, the Minister said. Rounded ecosystem Hyderabad has emerged as a complete healthcare and life sciences ecosystem, from contributing to drug discovery and clinical trials to playing host to world-class hospitals and affordable, high-quality patient care. 'We are proud to host eight of the top ten global pharma companies, five of India's leading healthcare chains and over 230 U.S Food and Drug Administration (U.S FDA)-approved manufacturing facilities,' Babu said. Telangana contributes nearly one-third of India's pharmaceutical production and 40% of bulk drug exports from the country. 'With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system,' he said. Agilent's new facility is poised to serve as a hub for innovation and collaboration, supporting development of biologics, biosimilars and precision medicine, the Minister's office said. 'India is a strategic growth market for Agilent,' Agilent president and CEO Padraig McDonnell said. Serving as foundation for the new centre is Hyderabad's mature and future-focused life sciences ecosystem that thrives on deep industry expertise, strong research and development capabilities and a supportive policy environment. With its legacy in generics and a focus on advanced therapies, the city is well-positioned for the next phase of healthcare innovation. Without mentioning either the investment or hiring plans, Agilent said its capital investment in the facility is part of a broader three-to-five-year India growth strategy. The India Solution Centre in Manesar launched earlier this year further is a reflection of its commitment to enhance presence and capabilities in one of its fastest-growing, high-priority markets globally.
Yahoo
29-07-2025
- Business
- Yahoo
Agilent Tech looks to double investments in India, eyes high-teen growth, CEO says
By Rishika Sadam HYDERABAD (Reuters) -U.S.-based laboratory equipment maker Agilent Technologies plans to double its investments in India to expand in one of its fastest-growing markets, a top executive said. The company anticipates the Indian market to grow in the high teens and beyond, CEO Padraig McDonnell told Reuters, during the inauguration of its center in Hyderabad, a city in southern India. CEO McDonnell said the company plans to double its investments in India over the next three years, without specifying the amount, and added, "Before the end of the year, we're going to have new announcements about investments in India." Agilent generated revenue of $6.51 billion in the previous fiscal year, with the U.S. being its largest market. It produces laboratory equipment used in research, production and testing by pharmaceutical, chemical and food companies. "We're evenly split across markets, like one-third from the U.S., Europe and Asia," McDonnell said. However, he declined to provide details on India's contribution to total revenue, noting only that it is growing in double digits. The soaring demand for weight-loss drugs and drugmakers racing to develop their own versions is expected to boost demand for Agilent's services, McDonnell said. Indian drugmakers are working on developing cheaper versions of Novo Nordisk's blockbuster obesity drug Wegovy. Agilent has already observed such demand in other markets, and anticipates growth in its order book as more Indian pharmaceutical companies develop drugs for complex diseases, and work on cell and gene therapies, according to McDonnell. "All these spaces are very fast-growing markets. So we expect these drivers to continue to grow. And that's why we want to kind of invest ahead of the curve," he said, adding that India is expected to be a bigger growth driver of overall revenue in the coming years. Sign in to access your portfolio
